Drug news
NICE now recommends Colobreathe (Forest Labs)for Cystic Fibrosis infections.
NICE now recommends Colobreathe(colistimethate dry powder for inhalation) from Forest Labs as an option for treating chronic pulmonary infection caused by Pseudomonas aeruginosa in people with Cystic Fibrosis.
Colobreathe is recommended for those patients who would clinically benefit from continued Colobreathe treatment, but do not tolerate it in its nebulised form and the positive recommendation is subject to a discount in price.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins